Navidea Biopharmaceuticals (NAVB) Competitors

Vincerx Pharma (NASDAQ:VINC) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Which has preferable valuation & earnings, VINC or NAVB?

Navidea Biopharmaceuticals has higher revenue and earnings than Vincerx Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$20.60	0.00
Navidea Biopharmaceuticals	$8.13K	6.16	-$15.18M	N/A	N/A

Is VINC or NAVB more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Navidea Biopharmaceuticals	N/A	N/A	N/A

Does the media prefer VINC or NAVB?

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Navidea Biopharmaceuticals	Neutral

Do insiders and institutionals hold more shares of VINC or NAVB?

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, VINC or NAVB?

Vincerx Pharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Do analysts rate VINC or NAVB?

Vincerx Pharma presently has a consensus price target of $40.00, suggesting a potential upside of 103,259.17%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vincerx Pharma is more favorable than Navidea Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Navidea Biopharmaceuticals beats Vincerx Pharma on 5 of the 9 factors compared between the two stocks.